These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 5369679)

  • 41. [Chemotherapy of neoplasms].
    Osswald H
    Hippokrates; 1967 Jul; 38(13):497-506. PubMed ID: 5611578
    [No Abstract]   [Full Text] [Related]  

  • 42. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice.
    Knight V; Koshkina N; Waldrep C; Giovanella BC; Kleinerman E; Gilbert B
    Trans Am Clin Climatol Assoc; 2000; 111():135-45. PubMed ID: 10881338
    [No Abstract]   [Full Text] [Related]  

  • 43. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
    Peer D; Dekel Y; Melikhov D; Margalit R
    Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Experimental research on the antineoplastic activity of osaĭin].
    Shvarev IF; Tsetlin AL; Nikol'skaia BS; Nikonov GK
    Vopr Onkol; 1966; 12(3):64-6. PubMed ID: 5991963
    [No Abstract]   [Full Text] [Related]  

  • 45. [Kinetic aspects of experimental cancer chemotherapy].
    Erokhin VN; Konovalova NP; Ostrovskaia LA
    Izv Akad Nauk SSSR Biol; 1975; (5):747-58. PubMed ID: 1176702
    [No Abstract]   [Full Text] [Related]  

  • 46. Topical use of cancerocidal agents in an experimental model.
    Zwaveling A; Vroom EM
    Arch Chir Neerl; 1966; 18(4):273-82. PubMed ID: 5971515
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of 6-azauridine on plasma cell tumors of mice: correlation of antitumor effect with inhibition of orotic acid metabolism.
    Conn HO; Creasey WA; Calabresi P
    Cancer Res; 1967 Apr; 27(4):618-25. PubMed ID: 6071670
    [No Abstract]   [Full Text] [Related]  

  • 48. Experimental chemotherapy of murine melanomas: is there a discrepancy compared to clinical experience?
    Borovanský J
    Neoplasma; 1997; 44(5):277-81. PubMed ID: 9473785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy studies in an animal tumor spectrum. 3. Evaluation of the toxicity differential index.
    Mountain IM; Cappuccino JG; Mueller CH; Ritter FW; Schmid FA; Smol BA; Tarnowski GS
    Cancer Res; 1966 Feb; 26(2):258-64. PubMed ID: 5903177
    [No Abstract]   [Full Text] [Related]  

  • 50. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing growth and response to therapy in murine tumor models.
    Reynolds CP; Sun BC; DeClerck YA; Moats RA
    Methods Mol Med; 2005; 111():335-50. PubMed ID: 15911989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening data from the Cancer Chemotherapy National Service Center screening laboratories. XXXV.
    Schepartz SA; Abbott BJ; Leiter J
    Cancer Res; 1966 Aug; 26(8 Pt 2):950-1113. PubMed ID: 5950748
    [No Abstract]   [Full Text] [Related]  

  • 53. [Dose intensity in cancer chemotherapy: definition, average relative dose intensity and effective dose intensity].
    Alberto P
    Bull Cancer; 1995; 82 Suppl 1():3s-8s. PubMed ID: 7626852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors.
    Leonetti C; Scarsella M; Riggio G; Rizzo A; Salvati E; D'Incalci M; Staszewsky L; Frapolli R; Stevens MF; Stoppacciaro A; Mottolese M; Antoniani B; Gilson E; Zupi G; Biroccio A
    Clin Cancer Res; 2008 Nov; 14(22):7284-91. PubMed ID: 19010844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effecrs and side-effects of cancer chemotherapy, with special reference to multi-agent therapy].
    Kimura K; Konda C; Kitahara T; Suzuki A; Fujita H
    Nihon Rinsho; 1968 Jul; 26(7):1595-602. PubMed ID: 5751011
    [No Abstract]   [Full Text] [Related]  

  • 56. A quick reference chart on cross resistance between anticancer patients.
    Skipper HE; Hutchison DJ; Schabel FM; Schmidt LH; Goldin A; Brockman RW; Venditti JM; Wodinsky I
    Cancer Chemother Rep; 1972 Aug; 56(4):493-8. PubMed ID: 5081592
    [No Abstract]   [Full Text] [Related]  

  • 57. [Combined drug therapy and its significance].
    Ota K
    Nihon Rinsho; 1969 Jun; 27(6):1571-7. PubMed ID: 5816826
    [No Abstract]   [Full Text] [Related]  

  • 58. Intensive cancer chemotherapy.
    Tattersall MH; Tobias JS
    Lancet; 1977 Jan; 1(8003):141-2. PubMed ID: 64672
    [No Abstract]   [Full Text] [Related]  

  • 59. The contribution of animal experiments to knowledge of the relationship between diet and cancer risk in humans.
    O'Connor TP; Campbell TC
    Cancer Surv; 1987; 6(4):573-83. PubMed ID: 3330680
    [No Abstract]   [Full Text] [Related]  

  • 60. Primary chemotherapy: concepts and issues.
    Muggia FM
    Prog Clin Biol Res; 1985; 201():377-83. PubMed ID: 4095118
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.